Globus Medical (GMED) Tops Q1 EPS by 2c, Raises FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Globus Medical, Inc. (GMED) Reports Revenue Well Above Consensus, Brean Capital Note; PT to $33
May 6, 2015 7:13 AM EDTBrean Capital reiterates their Buy rating on Globus Medical, Inc. (NYSE: GMED) and raised the target price to $33 (from $30) after GMED posted revenues well above consensus. GMED's 1Q15 report showed and increase of 15.2% in revenues to $131.6 million. Despite lower margins, new products and... More
